Premenstrual dysphoric disorder (PMDD) is a mood disorder characterized by emotional, cognitive, and physical symptoms. PMDD can cause significant distress and impairment during the luteal phase of the menstrual cycle (between ovulation and menstruation). Symptoms typically improve within a few days after the onset of menses, and are minimal or absent in the week after menses. PMDD has a profound impact on an individual's quality of life and dramatically increases the risk of suicidal ideation and even suicide attempts. Many women experience discomfort or mild mood changes before menstruation, but 5–8% experience severe premenstrual syndrome (PMS), causing significant distress or functional impairment. Within this group, some will meet the criteria for PMDD. PMDD's exact cause is unknown. Ovarian hormone levels during the menstrual cycle do not differ between those with PMDD and the general population. But because symptoms are present only during ovulatory cycles and resolve after menstruation, it is believed to be caused by fluctuations in gonadal sex hormones or variations in sensitivity to sex hormones. In 2017, National Institutes of Health researchers discovered that women with PMDD have genetic changes that make their emotional regulatory pathways more sensitive to estrogen and progesterone, as well as their chemical derivatives. The researchers believe this increased sensitivity may cause PMDD symptoms. PMDD was added to the list of depressive disorders in the Diagnostic and Statistical Manual of Mental Disorders in 2013. It has 11 main symptoms, of which five must be present for a PMDD diagnosis. Roughly 20% of females have some PMDD symptoms, but either have fewer than five or do not have functional impairment. The first-line treatment for PMDD is with selective serotonin reuptake inhibitors (SSRIs), which can be administered continuously throughout the menstrual cycle or intermittently, with treatment only during the symptomatic phase (approximately 14 days per cycle). Hormonal therapy with oral contraceptives that contain drospirenone have also demonstrated efficiency in reducing PMDD symptoms. Cognitive behavioral therapy, whether in combination with SSRIs or alone, has shown to be effective in reducing impairment. Dietary modifications and exercise may also be helpful, but studies investigating these treatments have not demonstrated efficacy in reducing PMDD symptoms.
Signs and symptoms Clinicians consider mood symptoms, physical symptoms, and impact on the patient's life in making the diagnosis of PMDD. Mood symptoms include dysphoria, emotional lability (rapidly changing emotions), irritability and anger that may lead to conflict, anxiety, feeling on edge, hopelessness, difficulty concentrating, appetite changes, sleeping more or less than usual, or feeling out of control. The physical symptoms are similar to the symptoms of premenstrual syndrome, such as breast tenderness or swelling, joint pain, muscle pain, weight gain, and bloating. Because of the broad variety in clinical presentation, the onset of symptoms only during or around the luteal phase is key for diagnosing someone with PMDD rather than any other mood disorders. PMDD follows a predictable, cyclic pattern. Symptoms begin in the late luteal phase of the menstrual cycle (after ovulation) and end or are markedly reduced shortly after menstruation begins. On average, the symptoms last six days but can start up to two weeks before menses, meaning symptoms can be felt for up to three weeks out of a cycle. Severe symptoms can begin and worsen until the onset of menstruation, with many not feeling relief until a few days after menstruation ends. The most intense symptoms occur in the week and days leading up to the first day of menstrual blood flow. The symptoms usually cease shortly after the start of the menstrual period or a few days after it ends. Various symptom and severity tracking questionnaires exist to document presence and severity of symptoms throughout consecutive menstrual cycles. The International Society for the Study of Premenstrual Disorders (ISPMD) defines two categories of premenstrual disorders: core PMD and variant PMD. Core PMD has six characteristics, mainly focusing on the cyclical nature of PMDD and its typical onset pre-menses tracked for more than two menstrual cycles. The four classified variant PMDs involve more unexpected variables that cause the onset of premenstrual distress, such as PMD with absent menstruation or premenstrual exacerbation, wherein the symptoms of another preexisting psychological disorder may be heightened as a result of PMDD onset.
Epidemiology About 5–8% of women who are of reproductive age experience severe premenstrual syndrome; most of them also meet the criteria for PMDD.
… excerpt ends here. Continue reading the full article.
